Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

The purification challenge behind engineered antibody drugs for cancer

Many clinically relevant molecules fall by the wayside because of the complex challenge of purifying them at industrial scale. That’s why un

<![CDATA[Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma ]]>

<![CDATA[Relapsed/Refractory Multiple Myeloma: Interpreting MonumenTAL-3 Efficacy and Safety Findings]]>

Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL

Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly a

<![CDATA[Relapsed/Refractory Multiple Myeloma: Rationale and Design of the MonumenTAL-3 Study]]>

https://doi.org/10.1056/NEJMoa2517384

Phase 3 trial: Mim8, a bispecific antibody for hemophilia A (± inhibitors). Patients ≥12 received weekly/monthly doses based on weight. PMID